Genetic ablation of epidermal EGFR reveals the dynamic origin of adverse effects of anti-EGFR therapy

Science Translational Medicine

Volumn 5, Issue 199, 2013, Pages

  Mascia, Francesca ^a   Lam, Gary ^a   Keith, Christopher ^a   Garber, Caroline ^a   Steinberg, Seth M ^a   Kohn, Elise ^a   Yuspa, Stuart H ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR CCR2; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; INDUCIBLE NITRIC OXIDE SYNTHASE; MESSENGER RNA; MYELOID DIFFERENTIATION FACTOR 88; TUMOR NECROSIS FACTOR ALPHA RECEPTOR;

ACNE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; CELL INFILTRATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE MODEL; DRUG ERUPTION; EOSINOPHIL; EPIDERMIS; FEMALE; GENE EXPRESSION; GENETIC ABLATION; GENETIC PROCEDURES; HUMAN; HUMAN TISSUE; LEUKOCYTE COUNT; MACROPHAGE; MACULOPAPULAR RASH; MALE; MAST CELL; MOUSE; NEUTROPHIL; NONHUMAN; OVARY CANCER; PLASMA; PRIORITY JOURNAL; PRURITUS; SIGNAL TRANSDUCTION; SKIN RASH SYNDROME; T LYMPHOCYTE;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD CELL COUNT; CHEMOKINES; DISEASE MODELS, ANIMAL; EXANTHEMA; FEMALE; GENES, ERBB-1; HUMANS; INFLAMMATION MEDIATORS; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OVARIAN NEOPLASMS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, MESSENGER; SKIN; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84883884440     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3005773     Document Type: Article

References (40)

1. F. Ciardiello, G. Tortora, EGFR antagonists in cancer treatment. N. Engl. J. Med. 358, 1160-1174 (2008).
2. M. E. Lacouture, Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat. Rev. Cancer 6, 803-812 (2006).
3. M. Peeters, S. Siena, E. Van Cutsem, A. Sobrero, A. Hendlisz, S. Cascinu, H. Kalofonos, G. Devercelli, M. Wolf, R. G. Amado, Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy. Cancer 115, 1544-1554 (2009).
4. R. Peréz-Soler, L. Saltz, Cutaneous adverse effects with HER1/EGFR-targeted agents: Is there a silver lining? J. Clin. Oncol. 23, 5235-5246 (2005).
5. B. Wacker, T. Nagrani, J. Weinberg, K. Witt, G. Clark, P. J. Cagnoni, Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin. Cancer Res. 13, 3913-3921 (2007).
6. E. Guttman-Yassky, A. Mita, M. De Jonge, L. Matthews, S. McCarthy, K. K. Iwata, J. Verweij, E. K. Rowinsky, J. G. Krueger, Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib. Eur. J. Cancer 46, 2010-2019 (2010).
7. S. S. Han, M. Lee, G. H. Park, S. H. Bang, Y. K. Kang, T. W. Kim, J. L. Lee, H. M. Chang, M. H. Ryu, Investigation of papulopustular eruptions caused by cetuximab treatment shows altered differentiation markers and increases in inflammatory cytokines. Br. J. Dermatol. 162, 371-379 (2010).
8. L. A. Hansen, N. Alexander, M. E. Hogan, J. P. Sundberg, A. Dlugosz, D. W. Threadgill, T. Magnuson, S. H. Yuspa, Genetically null mice reveal a central role for epidermal growth factor receptor in the differentiation of the hair follicle and normal hair development. Am. J. Pathol. 150, 1959-1975 (1997).
9. R. Murillas, F. Larcher, C. J. Conti, M. Santos, A. Ullrich, J. L. Jorcano, Expression of a dominant negative mutant of epidermal growth factor receptor in the epidermis of transgenic mice elicits striking alterations in hair follicle development and skin structure. EMBO J. 14, 5216-5223 (1995).
10. M. Sibilia, B. Wagner, A. Hoebertz, C. Elliott, S. Marino, W. Jochum, E. F. Wagner, Mice humanised for the EGF receptor display hypomorphic phenotypes in skin, bone and heart. Development 130, 4515-4525 (2003).
11. F. Mascia, V. Mariani, G. Girolomoni, S. Pastore, Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation. Am. J. Pathol. 163, 303-312 (2003).
12. S. Pastore, F. Mascia, F. Mariotti, C. Dattilo, V. Mariani, G. Girolomoni, ERK1/2 regulates epidermal chemokine expression and skin inflammation. J. Immunol. 174, 5047-5056 (2005).
13. D. C. Blaydon, P. Biancheri, W. L. Di, V. Plagnol, R. M. Cabral, M. A. Brooke, D. A. van Heel, F. Ruschendorf, M. Toynbee, A. Walne, E. A. O'Toole, J. E. Martin, K. Lindley, T. Vulliamy, D. J. Abrams, T. T. MacDonald, J. I. Harper, D. P. Kelsell, Inflammatory skin and bowel disease linked to ADAM17 deletion. N. Engl. J. Med. 365, 1502-1508 (2011).
14. A. Argiris, S. C. Lee, T. Feinstein, S. Thomas, B. F. Branstetter IV, R. Seethala, L. Wang, W. Gooding, J. R. Grandis, R. L. Ferris, Serum biomarkers as potential predictors of antitumor activity of cetuximab-containing therapy for locally advanced head and neck cancer. Oral Oncol. 47, 961-966 (2011).
15. A. Debucquoy, K. Haustermans, A. Daemen, S. Aydin, L. Libbrecht, O. Gevaert, B. De Moor, S. Tejpar, W. H. McBride, F. Penninckx, P. Scalliet, C. Stroh, S. Vlassak, C. Sempoux, J. P. Machiels, Molecular response to cetuximab and efficacy of preoperative cetuximab-based chemoradiation in rectal cancer. J. Clin. Oncol. 27, 2751-2757 (2009).
16. S. Kanazawa, K. Yamaguchi, Y. Kinoshita, Y. Komiyama, M. Muramatsu, S. Nomura, Elevation of soluble interleukin-2 receptor in patients with non-small cell lung cancer treated with gefitinib. J. Cancer Res. Clin. Oncol. 132, 719-725 (2006).
17. H. Kimura, K. Kasahara, M. Sekijima, T. Tamura, K. Nishio, Plasma MIP-1b levels and skin toxicity in Japanese non-small cell lung cancer patients treated with the EGFR-targeted tyrosine kinase inhibitor, gefitinib. Lung Cancer 50, 393-399 (2005).
18. E. M. Posadas, M. S. Liel, V. Kwitkowski, L. Minasian, A. K. Godwin, M. M. Hussain, V. Espina, B. J. Wood, S. M. Steinberg, E. C. Kohn, A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer. Cancer 109, 1323-1330 (2007).
19. A. Ramirez, A. Page, A. Gandarillas, J. Zanet, S. Pibre, M. Vidal, L. Tusell, A. Genesca, D. A. Whitaker, D. W. Melton, J. L. Jorcano, A keratin K5Cre transgenic line appropriate for tissue-specific or generalized Cre-mediated recombination. Genesis 39, 52-57 (2004).
20. T. C. Lee, D. W. Threadgill, Generation and validation of mice carrying a conditional allele of the epidermal growth factor receptor. Genesis 47, 85-92 (2009).
21. J. A. Segre, Epidermal barrier formation and recovery in skin disorders. J. Clin. Invest. 116, 1150-1158 (2006).
22. D. W. Threadgill, A. A. Dlugosz, L. A. Hansen, T. Tennenbaum, U. Lichti, D. Yee, C. LaMantia, T. Mourton, K. Herrup, R. C. Harris, J. A. Barnard, S. H. Yuspa, R. J. Coffey, T. Magnuson, Targeted disruption of mouse EGF receptor: Effect of genetic background on mutant phenotype. Science 269, 230-234 (1995).
23. C. Cataisson, A. J. Pearson, S. Torgerson, S. A. Nedospasov, S. H. Yuspa, Protein kinase Camediated chemotaxis of neutrophils requires NF-kB activity but is independent of TNFa signaling in mouse skin in vivo. J. Immunol. 174, 1686-1692 (2005).
24. O. Adachi, T. Kawai, K. Takeda, M. Matsumoto, H. Tsutsui, M. Sakagami, K. Nakanishi, S. Akira, Targeted disruption of the MyD88 gene results in loss of IL-1-and IL-18-mediated function. Immunity 9, 143-150 (1998).
25. V. E. Laubach, E. G. Shesely, O. Smithies, P. A. Sherman, Mice lacking inducible nitric oxide synthase are not resistant to lipopolysaccharide-induced death. Proc. Natl. Acad. Sci. U.S.A. 92, 10688-10692 (1995).
26. W. A. Kuziel, S. J. Morgan, T. C. Dawson, S. Griffin, O. Smithies, K. Ley, N. Maeda, Severe reduction in leukocyte adhesion and monocyte extravasation in mice deficient in CC chemokine receptor 2. Proc. Natl. Acad. Sci. U.S.A. 94, 12053-12058 (1997).
27. R. Zaynagetdinov, T. P. Sherrill, V. V. Polosukhin, W. Han, J. A. Ausborn, A. G. McLoed, F. B. McMahon, L. A. Gleaves, A. L. Degryse, G. T. Stathopoulos, F. E. Yull, T. S. Blackwell, A critical role for macrophages in promotion of urethane-induced lung carcinogenesis. J. Immunol. 187, 5703-5711 (2011).
28. N. Van Rooijen, A. Sanders, Liposome mediated depletion of macrophages: Mechanism of action, preparation of liposomes and applications. J. Immunol. Methods 174, 83-93 (1994).
29. F. Mascia, M. Denning, R. Kopan, S. H. Yuspa, The black box illuminated: Signals and signaling. J. Invest. Dermatol. 132, 811-819 (2012).
30. D. Surguladze, D. Deevi, N. Claros, E. Corcoran, S. Wang, M. J. Plym, Y. Wu, J. Doody, D. J. Mauro, L. Witte, K. J. Busam, B. Pytowski, U. Rodeck, J. R. Tonra, Tumor necrosis factor-a and interleukin-1 antagonists alleviate inflammatory skin changes associated with epidermal growth factor receptor antibody therapy in mice. Cancer Res. 69, 5643-5647 (2009).
31. B. M. Lichtenberger, P. A. Gerber, M. Holcmann, B. A. Buhren, N. Amberg, V. Smolle, H. Schrumpf, E. Boelke, P. Ansari, C. Mackenzie, A. Wollenberg, A. Kislat, J. W. Fischer, K. Röck, J. Harder, J. M. Schröder, B. Homey, M. Sibilia, Epidermal EGFR controls cutaneous host defense and prevents inflammation. Sci. Transl. Med. 5, 199ra111 (2013).
32. P. A. Gerber, B. A. Buhren, F. Cevikbas, E. Bölke, M. Steinhoff, B. Homey, Preliminary evidence for a role of mast cells in epidermal growth factor receptor inhibitor-induced pruritus. J. Am. Acad. Dermatol. 63, 163-165 (2010).
33. M. Gnant, P. Clézardin, Direct and indirect anticancer activity of bisphosphonates: A brief review of published literature. Cancer Treat. Rev. 38, 407-415 (2012).
34. S. Kinugawa, M. Koide, Y. Kobayashi, T. Mizoguchi, T. Ninomiya, A. Muto, I. Kawahara, M. Nakamura, H. Yasuda, N. Takahashi, N. Udagawa, Tetracyclines convert the osteoclastic-differentiation pathway of progenitor cells to produce dendritic cell-like cells. J. Immunol. 188, 1772-1781 (2012).
35. M. E. Lacouture, M. J. Anadkat, R. J. Bensadoun, J. Bryce, A. Chan, J. B. Epstein, B. Eaby-Sandy, B. A. Murphy; MASCC Skin Toxicity Study Group, Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer 19, 1079-1095 (2011).
36. P. E. Dubé, F. Yan, S. Punit, N. Girish, S. J. McElroy, M. K. Washington, D. B. Polk, Epidermal growth factor receptor inhibits colitis-associated cancer in mice. J. Clin. Invest. 122, 2780-2792 (2012).
37. F. Yan, H. Cao, T. L. Cover, M. K. Washington, Y. Shi, L. Liu, R. Chaturvedi, R. M. Peek Jr., K. T. Wilson, D. B. Polk, Colon-specific delivery of a probiotic-derived soluble protein ameliorates intestinal inflammation in mice through an EGFR-dependent mechanism. J. Clin. Invest. 121, 2242-2253 (2011).
38. P. P. Bradley, D. A. Priebat, R. D. Christensen, G. Rothstein, Measurement of cutaneous inflammation: Estimation of neutrophil content with an enzyme marker. J. Invest. Dermatol. 78, 206-209 (1982).
39. U. Lichti, J. Anders, S. H. Yuspa, Isolation and short-term culture of primary keratinocytes, hair follicle populations and dermal cells from newborn mice and keratinocytes from adult mice for in vitro analysis and for grafting to immunodeficient mice. Nat. Protoc. 3, 799-810 (2008).
40. F. Mascia, G. Lam, C. Keith, C. Garber, S. M. Steinberg, E. Kohn, S. H. Yuspa, Genetic ablation of epidermal EGFR reveals the dynamic origin of adverse effects of anti-EGFR therapy. Sci. Transl. Med. 5, 199ra110 (2013).